Luigi Fattore

List of Publications by Year
in descending order

32 papers	816 citations	471509 17 h-index	501196 28 g-index
32 all docs	32 docs citations	32 times ranked	1611 citing authors

#	Article	IF	Citations
1	Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. , 2022, 10, e004239.		6
2	The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 645069.	2.8	18
3	CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions. Journal of Cellular Physiology, 2020, 235, 1877-1887.	4.1	29
4	Drug tolerance to target therapy in melanoma revealed at single cell level: What next?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188440.	7.4	12
5	Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma. Cancers, 2020, 12, 3368.	3.7	15
6	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. Cell Communication and Signaling, 2020, 18, 150.	6.5	4
7	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. International Journal of Molecular Sciences, 2020, 21, 1930.	4.1	15
8	microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	4.9	30
9	Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Cell Death and Disease, 2019, 10, 827.	6.3	35
10	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers, 2019, 11, 1425.	3.7	22
11	c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells. International Journal of Molecular Sciences, 2019, 20, 320.	4.1	8
12	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. Expert Opinion on Therapeutic Targets, 2019, 23, 53-68.	3.4	6
13	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death and Differentiation, 2019, 26, 1267-1282.	11.2	47
14	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 318.	8.6	66
15	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	4.4	2
16	Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts. Journal of Translational Medicine, 2017, 15, .	4.4	1
17	Selective targeting of point-mutated KRAS through artificial microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4203-E4212.	7.1	38
18	MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine and Growth Factor Reviews, 2017, 36, 39-48.	7.2	26

#	Article	IF	Citations
19	MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 2017, 8, 22262-22278.	1.8	89
20	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	7.1	99
21	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
22	Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma. , 2016, , .		2
23	ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors. Journal of Translational Medicine, 2015, 13, .	4.4	2
24	Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR). Food and Chemical Toxicology, 2015, 76, 77-79.	3.6	25
25	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget, 2015, 6, 24823-24841.	1.8	29
26	Abstract 4230: Targeting lung cancer stem cells through fatty acid metabolism. , 2015, , .		0
27	Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition. Journal of Translational Medicine, 2014, 12, O2.	4.4	0
28	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Journal of Translational Medicine, 2013, 11, 180.	4.4	61
29	TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung. Cell Cycle, 2013, 12, 1696-1703.	2.6	30
30	Role of WT1â€“ZNF224 interaction in the expression of apoptosis-regulating genes. Human Molecular Genetics, 2013, 22, 1771-1782.	2.9	20
31	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer. Oncotarget, 2013, 4, 1253-1265.	1.8	38
32	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle, 2012, 11, 1455-1467.	2.6	29